Premium
O1‐10‐02: NEUROGRANIN PREDICTS LONGITUDINAL COGNITIVE DECLINE IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT
Author(s) -
Sun Xiaoyan,
Headley Alison,
De Leon-Benedetti Andres,
Dong Chuanhui,
Zetterberg Henrik,
Blennow Kaj,
Loewenstein David A.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.2385
Subject(s) - neurogranin , cognitive decline , cognition , psychology , alzheimer's disease neuroimaging initiative , medicine , cerebrospinal fluid , effects of sleep deprivation on cognitive performance , episodic memory , audiology , cognitive impairment , neuroscience , dementia , disease , chemistry , biochemistry , protein kinase c , enzyme
Val66 homozygotes, Met66 carriers showed greater decline in episodic memory (p1⁄4.023), increase in CSF tau (p1⁄4.012), and increase in CSF ptau181 (p1⁄4.017). CSF Ab42 levels over time did not differ significantly between groups (p1⁄4.272). Conclusions:In individuals with abnormal levels of amyloid, Met66 carriers showed increased decline in episodic memory and increases in CSF tau and ptau181 when compared to Val66 homozygotes. This is consistent with previous observations in younger adults with autosomal dominant AD where mutation carriers who were Met66 carriers showed faster deterioration in episodic memory accompanied by increases in CSF tau and ptau181, but not in Ab42 accumulation. These data converge to show that BDNF Val66Met is an important moderator of neurodegenerative processes in AD.